Assessing the clinical impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on metastatic neuroendocrine tumors: A multicenter real-world data from Türkiye

Basit Öğe Kaydı
dc.authorid0000-0001-7858-8180en_US
dc.authorid0000-0002-7931-2941en_US
dc.contributor.authorÜnal, Çağlar
dc.contributor.authorSelçuk, Nalan Alan
dc.contributor.authorBiricik, Fatih Selçuk
dc.contributor.authorAlan, Özkan
dc.contributor.authorOrdu, Çetin
dc.contributor.authorSelvi, Oğuzhan
dc.contributor.authorKalkan, Ziya
dc.contributor.authorOruç, Zeynep
dc.date.accessioned2024-01-16T06:41:09Z
dc.date.available2024-01-16T06:41:09Z
dc.date.issued2023en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalıen_US
dc.description.abstractObjectives: This study aimed to evaluate the clinical outcomes, including progression-free survival (PFS), overall survival (OS), Objective Response Rate (ORR), and Disease Control Rate (DCR), in patients received Lutetium-177 (Lu-177) DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) for metastatic neuroendocrine tumors. This study further stratified outcomes based on tumor grade, Ki-67 status, primary tumor localization, number of treatment cycles, and associated adverse effects. Methods: We conducted a multicenter retrospective study analyzing the data of 73 patients with metastatic NETs across 17 different hospitals in various regions of Türkiye. A total of 73 metastatic NET patients underwent Lu-177 DOT-ATATE PRRT between December 2013 and March 2023. Results: Over a median follow-up of 52.7 months, patients showed a median PFS of 13.7 months and OS of 51.2 months. The ORR was 29.6%, and the DCR was 66.2%. Grade 1 and 2 tumor patients had superior outcomes (PFS: 16.9 months, OS: 55.5 months) compared to grade 3 tumor patients (PFS: 8.5 months, OS: 29.5 months). Based on their Ki-67 status, those ≤ 20% had prolonged PFS (16.9 months) and OS (55.5 months) than those between 21 and 55% (PFS: 5.9 months, OS: 41.3 months). Regarding primary tumor localization, the PFS values were 13.1, 15.3, 13.7, and 8.6 months for pancreatic, GIS, lung, and unknown origin tumors, respectively. The OS across tumor types fluctuated between 41.1 and 54.1 months. Patients who received more than four cycles demonstrated significantly improved median PFS (22.4 months) and OS (90.3 months) compared to those who received ≤ 4 cycles (median PFS: 9.3 months; median OS: 41.8 months). Grade 3-4 adverse effects were observed in 21.9% of patients. Conclusion: Our findings affirm that PRRT is a potent and well-tolerated treatment for metastatic NETs. Notably, patients who received more than 4 cycles of PRRT experienced a markedly improved median PFS and OS compared to their counterparts who received ≤4 cycles.en_US
dc.identifier.citationÜnal, Ç., Selçuk, N. A., Biricik, F. S., Alan, Ö., Ordu, Ç., Selvi, O. ve diğerleri. (2023). Assessing the clinical impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on metastatic neuroendocrine tumors: A multicenter real-world data from Türkiye. Eurasian Journal of Medicine and Oncology, 7(3), 232-242.en_US
dc.identifier.doi10.14744/ejmo.2023.48337
dc.identifier.endpage242en_US
dc.identifier.issn2587-2400
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85175379046
dc.identifier.scopusqualityQ2
dc.identifier.startpage232en_US
dc.identifier.urihttps://www.scopus.com/record/display.uri?eid=2-s2.0-85175379046&origin=resultslist&sort
dc.identifier.urihttps://hdl.handle.net/11468/13209
dc.identifier.volume7en_US
dc.identifier.wosWOS:001135942300003
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorKalkan, Ziya
dc.institutionauthorOruç, Zeynep
dc.language.isoenen_US
dc.publisherKare Publishingen_US
dc.relation.ispartofEurasian Journal of Medicine and Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLutetium-177en_US
dc.subjectNeuroendocrine neoplasmen_US
dc.subjectNeuroendocrine tumorsen_US
dc.subjectPeptide receptor radionuclide therapyen_US
dc.subjectPRRTen_US
dc.subjectRadiolabeled somatostatin analoguesen_US
dc.titleAssessing the clinical impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on metastatic neuroendocrine tumors: A multicenter real-world data from Türkiyeen_US
dc.titleAssessing the clinical impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on metastatic neuroendocrine tumors: A multicenter real-world data from Türkiye
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Assessing the Clinical Impact of Lutetium177 DOTATATE Peptide Receptor Radionuclide Therapy PRRT on Metastatic Neuroendocrine Tumors A Multicenter RealWorld Data from Trkiye-48337.pdf
Boyut:
540.64 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu